论文部分内容阅读
目的 探讨多种血清肿瘤标志物联合检测在胰腺癌诊治中的应用价值。方法 采用荧光免疫分析法和放射免疫法检测胰腺癌病人的血清CA5 0、CA19 9、CA12 5和CA2 42的表达 ,重点动态观察胰腺癌诊治过程中肿瘤标志物的表达及其临床随访价值。结果 CA19 9、CA2 42、CA5 0和CA12 5平行联合检测可提高胰腺癌诊断的敏感性 (90 2 % ) ,系列联合检测可提高其特异性 (93 5 % ) ;结合电子束断层摄影 (EBCT)检查 ,更可增加胰腺癌诊断的敏感性 (98 6 % )和特异性 (94 6 % )。动态监测术后多种肿瘤标志物有助于肿瘤复发和转移的随访。结论 动态联合检测CA19 9、CA2 42、CA5 0和CA12 5结合EBCT检查 ,可增加胰腺癌诊断的敏感性和特异性
Objective To explore the value of combined detection of multiple serum tumor markers in the diagnosis and treatment of pancreatic cancer. Methods The expression of serum CA5 0, CA19 9, CA12 5 and CA2 42 in patients with pancreatic cancer was detected by fluorescence immunoassay and radioimmunoassay, and the expression of tumor markers and their clinical follow-up value during the diagnosis and treatment of pancreatic cancer were analyzed. Results The combined detection of CA19 9, CA2 42, CA5 0 and CA12 5 could improve the diagnostic sensitivity of pancreatic cancer (90 2%) and the combined detection of them increased the specificity (93 5%). Combination of electron beam tomography (EBCT ) Examination, but also increase the sensitivity of diagnosis of pancreatic cancer (98 6%) and specificity (94 6%). Dynamic monitoring of various tumor markers contributes to the follow-up of tumor recurrence and metastasis. Conclusions Dynamic joint detection of CA19 9, CA2 42, CA5 0 and CA12 5 in combination with EBCT can increase the sensitivity and specificity of the diagnosis of pancreatic cancer